Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Immunosuppression and HBV reactivation
Daniel Shouval
*
,
Oren Shibolet
*
Corresponding author for this work
Internal Medicine
Hadassah University Medical Centre
Research output
:
Contribution to journal
›
Article
›
peer-review
134
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Immunosuppression and HBV reactivation'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Immunosuppression
100%
Hepatitis B Virus Reactivation
100%
Chemotherapy
50%
Hepatitis B Surface Antigen (HBsAg)
50%
Antiviral Agents
50%
Stem Cells
25%
Low Dose Rate
25%
Corticosteroids
25%
Cancer Patients
25%
In Cancer
25%
Clinical Presentation
25%
Rheumatoid Arthritis
25%
Solid Tumors
25%
Lymphoma
25%
AIDS/HIV
25%
Bone Marrow Transplantation
25%
Lifesaving
25%
Autoimmune Disease
25%
Standard of Care
25%
Inflammatory Bowel Disease
25%
Alanine Aminotransferase
25%
Biological Agents
25%
Preemptive Treatment
25%
Rituximab
25%
Liver Failure
25%
Laboratory Signs
25%
Hepatitis B Virus DNA
25%
Hepatocellular Injury
25%
Lamivudine
25%
Hepatitis B Virus Replication
25%
Organ Transplant Recipients
25%
Asymptomatic Course
25%
Tenofovir
25%
Antigen Carrier
25%
Severe Hepatitis
25%
Entecavir
25%
Occult Hepatitis B Virus Infection
25%
Occult Hepatitis B Virus
25%
Medicine and Dentistry
Immunosuppressive Treatment
100%
Hepatitis B Virus
100%
Virus Reactivation
100%
Antivirus Agent
28%
Hepatitis B Antigen
28%
Malignant Neoplasm
14%
Solid Malignant Neoplasm
14%
Stem Cell
14%
Bone Marrow Transplantation
14%
Transplantation
14%
Autoimmune Disease
14%
High Risk Population
14%
Inflammatory Bowel Disease
14%
Rheumatoid Arthritis
14%
Alanine Aminotransferase
14%
Virus Replication
14%
Biological Product
14%
Hepatitis B
14%
Human Immunodeficiency Virus
14%
Rituximab
14%
Liver Failure
14%
Virus DNA
14%
Liver Cell Damage
14%
Lamivudine
14%
Tenofovir
14%
Entecavir
14%
Immunology and Microbiology
Immunosuppression
100%
Hepatitis B Virus
100%
Virus Reactivation
100%
HBsAg
28%
Hepatitis B Antigen
28%
Viral Replication
14%
Transplant Procedure
14%
Inflammatory Arthritis
14%
Stem Cell
14%
Bone Marrow Transplantation
14%
DNA Virus
14%
Human Immunodeficiency Virus
14%
Autoimmune Disease
14%
Biological Product
14%
Inflammatory Bowel Disease
14%
High Risk Population
14%
Hepatitis B
14%
Rituximab
14%
Tenofovir
14%
Pharmacology, Toxicology and Pharmaceutical Science
Hepatitis B Virus
100%
Chemotherapy
28%
Antivirus Agent
28%
Hepatitis B Antigen
28%
Malignant Neoplasm
14%
Rheumatoid Arthritis
14%
HIV
14%
Solid Malignant Neoplasm
14%
Biological Product
14%
Alanine Aminotransferase
14%
Autoimmune Disease
14%
Inflammatory Bowel Disease
14%
Hepatitis B
14%
Rituximab
14%
Virus DNA
14%
Liver Failure
14%
Liver Cell Damage
14%
Lamivudine
14%
Tenofovir
14%
Entecavir
14%